A dual role for genetically modified lymphocytes in cancer immunotherapy

Trends in Molecular Medicine

Volumn 18, Issue 4, 2012, Pages 193-200

  Russo, Vincenzo ^a   Bondanza, Attilio ^a   Ciceri, Fabio ^a   Bregni, Marco ^a   Bordignon, Claudio ^b,c   Traversari, Catia ^c   Bonini, Chiara ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c MOLMED S P A   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOCYTE ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR; VIRUS VECTOR;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL THERAPY; DNA MODIFICATION; DONOR LYMPHOCYTE INFUSION; GENE TRANSFER; GENETICALLY MODIFIED LYMPHOCYTE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOGENICITY; MELANOMA; NONHUMAN; PATIENT SAFETY; REVIEW; SOLID TUMOR; SUICIDE GENE; T LYMPHOCYTE; THERAPY EFFECT; TRANSGENE;

GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; T-LYMPHOCYTES;

BACTERIA (MICROORGANISMS);

EID: 84859425684     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2011.12.003     Document Type: Review

References (60)

1. Kolb H.J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008, 112:4371-4383.
2. Rosenberg S.A. Cell transfer immunotherapy for metastatic solid cancer - what clinicians need to know. Nat. Rev. Clin. Oncol. 2011, 8:577-585.
3. June C.H. Principles of adoptive T cell cancer therapy. J. Clin. Invest. 2007, 117:1204-1212.
4. + T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol. 2006, 24:5060-5069.
5. Anderson W.F. Human gene therapy. Science (New York) 1992, 256:808-813.
6. Barese C.N., Dunbar C.E. Contributions of gene marking to cell and gene therapies. Hum. Gene Ther. 2011, 22:659-668.
7. Seliger B., et al. HLA class I antigen abnormalities and immune escape by malignant cells. Semin. Cancer Biol. 2002, 12:3-13.
8. Eshhar Z. The T-body approach: redirecting T cells with antibody specificity. Handb. Exp. Pharmacol. 2008, 181:329-342.
9. Vago L., et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N. Engl. J. Med. 2009, 361:478-488.
10. Kershaw M.H., et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 2006, 12:6106-6115.
11. Lamers C.H., et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 2006, 24:e20-e22.
12. Kochenderfer J.N., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116:4099-4102.
13. Porter D.L., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 2011, 365:725-733.
14. Pule M.A., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 2008, 14:1264-1270.
15. Parmiani G., et al. Universal and stemness-related tumor antigens: potential use in cancer immunotherapy. Clin. Cancer Res. 2007, 13:5675-5679.
16. Morgan R.A., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (New York) 2006, 314:126-129.
17. Parkhurst M.R., et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 2011, 19:620-626.
18. Robbins P.F., et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 2011, 29:917-924.
19. + T cells against NY-ESO-1. N. Engl. J. Med. 2008, 358:2698-2703.
20. Lupo-Stanghellini M.T., et al. Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. Hum. Gene Ther. 2010, 21:241-250.
21. Bonini C., et al. The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol. Ther. J. Am. Soc. Gene Ther. 2007, 15:1248-1252.
22. Ciceri F., et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol. 2009, 10:489-500.
23. Riddell S.R., et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat. Med. 1996, 2:216-223.
24. Berger C., et al. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 2006, 107:2294-2302.
25. Traversari C., et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 2007, 109:4708-4715.
26. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
27. den Haan J.M., et al. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 2000, 192:1685-1696.
28. Russo V., et al. Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity. J. Clin. Invest. 2007, 117:3087-3096.
29. Fontana R., et al. Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients. Blood 2009, 113:1651-1660.
30. Jena B., et al. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010, 116:1035-1044.
31. Maher J., et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat. Biotechnol. 2002, 20:70-75.
32. Milone M.C., et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 2009, 17:1453-1464.
33. Kershaw M.H., et al. Dual-specific T cells combine proliferation and antitumor activity. Nat. Biotechnol. 2002, 20:1221-1227.
34. Morgan R.A., et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 2010, 18:843-851.
35. Ertl H.C., et al. Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. Cancer Res. 2010, 71:3175-3181.
36. Bendle G.M., et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med. 2010, 16:565-570.
37. Rosenberg S.A. Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. Mol. Ther. 2010, 18:1744-1745.
38. Cohen C.J., et al. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 2007, 67:3898-3903.
39. Kuball J., et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 2007, 109:2331-2338.
40. + T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 2005, 22:117-129.
41. Govers C., et al. T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing. Trends Mol. Med. 2010, 16:77-87.
42. Okamoto S., et al. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res. 2009, 69:9003-9011.
43. Robbins P.F., et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J. Immunol. 2008, 180:6116-6131.
44. Laugel B., et al. Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition. J. Biol. Chem. 2005, 280:1882-1892.
45. Varela-Rohena A., et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat. Med. 2008, 14:1390-1395.
46. Johnson L.A., et al. Gene therapy with human and mouse T cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114:535-546.
47. Gattinoni L., et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 2011, 17:1290-1297.
48. Forster R., et al. CCR7 and its ligands: balancing immunity and tolerance. Nat. Rev. Immunol. 2008, 8:362-371.
49. + T cells capable of self-renewal and differentiation into antileukemia effectors. Blood 2010, 117:6469-6478.
50. Watts T.H. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 2005, 23:23-68.
51. Bianchi M.E., Manfredi A.A. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol. Rev. 2007, 220:35-46.
52. Sancho D., et al. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 2009, 458:899-903.
53. Toes R.E., et al. CD4 T cells and their role in antitumor immune responses. J. Exp. Med. 1999, 189:753-756.
54. Boon T., et al. Human T cell responses against melanoma. Annu. Rev. Immunol. 2006, 24:175-208.
55. Acuto O., et al. Tailoring T-cell receptor signals by proximal negative feedback mechanisms. Nat. Rev. Immunol. 2008, 8:699-712.
56. June C.H., et al. Engineering lymphocyte subsets: tools, trials and tribulations. Nat. Rev. Immunol. 2009, 9:704-716.
57. Di Stasi A., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 2011, 365:1673-1683.
58. Serafini M., et al. Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Hum. Gene Ther. 2004, 15:63-76.
59. Villadangos J.A., et al. Outside looking in: the inner workings of the cross-presentation pathway within dendritic cells. Trends Immunol. 2007, 28:45-47.
60. + dendritic cells. J. Exp. Med. 2010, 207:1131-1134.